Motesanib

Motesanib
IUPAC name N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
Other names AMG 706
Identifiers
CAS number	453562-69-1 Y
PubChem	11667893
ChemSpider	9842625
Jmol-3D images	Image 1
SMILES O=C(c2cccnc2NCc1ccncc1)Nc3ccc4c(c3)NCC4(C)C
InChI InChI=InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
Properties
Molecular formula	C22H23N5O
Molar mass	373.45 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Motesanib (AMG 706) is an experimental drug candidate. It is an orally administered small molecule antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors.^[1] It is used as the phosphate salt motesanib diphosphate.

Clinical trials

In 2011, it was reported that a Phase III trial did not show benefit for advanced non-squamous non-small-cell lung carcinoma (NSCLC).^[1] The drug is separately undergoing Phase II evaluation as first-line therapy for breast cancer.^[1]

There has also been a clinical trial for thyroid cancer.^[2]

References

1. ^ ^{a b c} "Amgen and Takeda’s NSCLC Drug Fails in Phase III Study". 30 Mar 2011. http://www.genengnews.com/gen-news-highlights/amgen-and-takeda-s-nsclc-drug-fails-in-phase-iii-study/81244902/. 
2. ^ Motesanib Diphosphate Provides Anticancer Activity Among Patients with Progressive Thyroid Cancer, CancerConnect.com

External links

• Motesanib molecular details